|
1
|
Insull W Jr: The pathology of
atherosclerosis: plaque development and plaque responses to medical
treatment. Am J Med. 122(1 Suppl): S3–S14. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Molestina RE, Miller RD, Ramirez JA and
Summersgill JT: Infection of human endothelial cells with Chlamydia
pneumonia stimulates transendothelial migration of neutrophils and
monocytes. Infect Immun. 67:1323–1330. 1999.PubMed/NCBI
|
|
3
|
Schell WD and Myers JN: Regression of
atherosclerosis: a review. Prog Cardiovasc Dis. 39:483–496. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Badimon JJ, Fueter V and Badimon L: Role
of high density lipoproteins in the regression of atherosclerosis.
Circulation. 86:86–94. 1992.
|
|
5
|
Nordestgaard BG, Chapman MJ, Ray K, et al:
Lipoprotein(a) as a cardiovascular risk factor: current status. Eur
Heart J. 31:2844–2853. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gu HF, Tang CK and Yang YZ: Psychological
stress, immune response, and atherosclerosis. Atherosclerosis.
223:69–77. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jaup T, Allemann Y, Urban P, et al: The
Magnum wire for percutaneous coronary balloon angioplasty in 723
patients. J Invasive Cardiol. 7:259–264. 1995.PubMed/NCBI
|
|
8
|
Li DX, Ma ZL and Li C: Advances in the
study of vascular smooth muscle cells and molecular imaging of
atherosclerosis. Yi Xue Zong Shu. 18:2539–2542. 2012.(In
Chinese).
|
|
9
|
Yang GH: Pathology (5th). Beijing, China:
Beijing People's Health Publishing House. 122–126. 2001.
|
|
10
|
Tarchalski J, Guzik P and Wysocki H:
Correlation between the extent of coronary atherosclerosis and
lipid profile. Mol Cell Biochem. 246:25–30. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yuan Y, Li P and Ye J: Lipid homeostasis
and the formation of macrophage-derived foam cells in
atherosclerosis. Protein Cell. 3:173–181. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yin K and Tang C: Inflammation, lipid
metabolism dysfunction, and hypertension: active research fields in
atherosclerosis-related cardiovascular disease in China. Sci China
Life Sci. 54:976–979. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
West AM, Anderson JD, Meyer CH, et al:
Type of lipid lowering therapy impacts atherosclerosis progression
in peripheral arterial disease assessed by CMR. Cardiovascular
Magnetic Resonance. 12(Suppl 1): 1302010. View Article : Google Scholar
|
|
14
|
Mukhopadhyay R: Mouse models of
atherosclerosis: explaining critical roles of lipid metabolism and
inflammation. J Appl Genet. 54:185–192. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Stancu CS, Toma L and Sima AV: Dual role
of lipoproteins in endothelial cell dysfunction in atherosclerosis.
Cell Tissue Res. 349:433–446. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Imano H and Iso H: Epidemiology of
hypertriglyceridemia. Nihon Rinsho. 71:1528–1535. 2013.(In
Japanese). PubMed/NCBI
|
|
17
|
Shao K, Chen W and Li S: Effect of Xin Mai
Jia formula on rat with Atherosclerosis. Shi Zhen Guo Yi Guo Yao.
22:2480–2481. 2011.(In Chinese).
|
|
18
|
Wan J, Yin Y, Sun R, et al: Protective
effect of the ultra-filtration extract from Xin Mai Jia on human
aortic smooth muscle cell injury induced by hydrogen peroxide. Exp
Ther Med. 7:11–16. 2014.PubMed/NCBI
|
|
19
|
He J, Gu DF, Reynolds K, et al: Serum
total and lipoprotein cholesterol level and awareness, treatment,
and control of hypercholesterolemia in China. Circulation.
110:405–410. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
LaRosa JC, Grundy SM, Waters DD, et al:
Intensive lipid lowering with atorvastatin in patients with stable
coronary disease. N Eng J Med. 352:1425–1435. 2005. View Article : Google Scholar
|
|
21
|
Moghadasian MH: Experimental
atherosclerosis: a historical overview. Life Sci. 70:855–865. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rim SJ, Leong-Poi H, Lindner JR, et al:
Decrease in coronary blood flow reserve during hyperlipidemia is
secondary to an increase in blood viscosity. Circulation.
104:2704–2709. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang XinSheng, Guo Xiaochun, Zhu Yuchun,
et al: A research report of correlation between hyperlipidemia and
blood rheology. Shi Yan Yu Jian Yan Yi Xue. 2008.26(3): 345–346,
(In Chinese).
|
|
24
|
Ross R: Atherosclerosis - an inflammatory
disease. New Engl J Med. 340:115–126. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Reriani M, Raichlin E, Prasad A, et al:
Long-term administration of endothelin receptor antagonist improves
coronary endothelial function in patients with early
atherosclerosis. Circulation. 122:958–966. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li MW, Mian MO, Barhoumi T, et al:
Endothelin-1 overexpression exacerbates atherosclerosis and induces
aortic aneurysms in apolipoprotein E knockout mice. Arterioscler
Thromb Vasc Biol. 33:2306–2315. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dohi Y, Hahn AW, Boulanger CM, Bühler FR
and Lüscher TF: Endothelin stimulated by angiotensin II augments
contractility of spontaneously hypertensive rat resistance
arteries. Hypertension. 19:131–137. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Suen RS, Rampersad SN, Stewart DJ and
Courtman DW: Differential roles of endothelin-1 in angiotensin
II-induced atherosclerosis and aortic aneurysms in apolipoprotein
E-null mice. Am J Pathol. 179:1549–1559. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lovren F, Pan Y, Quan A, et al:
Angiotensin converting enzyme-2 confers endothelial protection and
attenuates atherosclerosis. Am J Physiol Heart Circ Physiol.
295:H1377–H1384. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gkaliagkousi E and Ferro A: Nitric oxide
signalling in the regulation of cardiovascular and platelet
function. Front Biosci (Landmark Ed). 16:1873–1897. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tarin C, Gomez M, Calvo E, López JA and
Zaragoza C: Endothelial nitric oxide deficiency reduces
MMP-13-mediated cleavage of ICAM-1 in vascular endothelium: a role
in atherosclerosis. Arterioscler Thromb Vasc Biol. 29:27–32. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sweazea KL and Walker BR: High fat feeding
impairs endothelin-1 mediated vasoconstriction through increased
iNOS-derived nitric oxide. Horm Metab Res. 43:470–476. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Karmazyn M, Sostaric JV and Gan XT: The
myocardial Na+/H+ exchanger: a potential therapeutic target for the
prevention of myocardial ischaemic and reperfusion injury and
attenuation of postinfarction heart failure. Drugs. 61:375–389.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Théroux P: Myocardial cell protection: a
challenging time for action and a challenging time for clinical
research. Circulation. 101:2874–2876. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Foy RA, Shimizu S and Paul RJ: The effect
of hypoxia on pHi in porcine coronary artery endothelium and smooth
muscle. A novel method for measurements in endothelial cells in
situ. Circ Res. 80:21–27. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yamamoto S, Matsui K, Itoh N and Ohashi N:
The effect of an Na+/H+ exchange inhibitor,
SM-20550, on ischemia/reperfusion-induced endothelial dysfunction
in isolated perfused rat hearts. Int J Tissue React. 23:1–7.
2001.PubMed/NCBI
|
|
37
|
Undem C, Rios EJ, Maylor J and Shimoda LA:
Endothelin-1 augments Na+/H+ exchange
activity in murine pulmonary arterial smooth muscle cells via Rho
kinase. PLoS One. 7:e463032012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nofer JR, Noll C, Feuerborn R, Assmann G
and Tepel M: Low density lipoproteins inhibit the
Na+/H+ antiport in human platelets via
activation of p38MAP kinase. Biochem Biophys Res Commun.
340:751–757. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Nofer JR, Tepel M, Kehrel B, et al: High
density lipoproteins enhance the Na+/H+
antiport in human platelets. Thromb Haemost. 75:635–641.
1996.PubMed/NCBI
|
|
40
|
Navab M, Anantharamaiah GM, Reddy ST, Van
Lenten BJ and Fogelman AM: HDL as a biomarker, potential
therapeutic target, and therapy. Diabetes. 58:2711–2717. 2009.
View Article : Google Scholar : PubMed/NCBI
|
